论文部分内容阅读
目的观察β2受体激动剂硫酸特布他林和利多卡因联合雾化吸入治疗哮喘的作用。方法选择符合中重度支气管哮喘诊断的病例69例,随机分为治疗组35例和对照组34例,用硫酸特布他林联合利多卡因雾化吸入治疗中重度急性发作期哮喘患者(治疗组)并与单用硫酸特布他林(对照组)进行比较。观察临床表现,监测患者呼气峰流速(PE-FR),第1秒用力呼气量(FEV1)、用力肺活量(FVC)的变化。结果所有患者治疗前PEFR、FEV1、FVC均小于预计值。用药后两组的PEFR、FEV1、FVC,均有较大幅度提高且临床症状明显得到控制,治疗组更为明显,两组差异有统计学意义(P<0.01)。结论硫酸特布他林联合利多卡因雾化吸入治疗中重度哮喘,临床症状的控制及肺功能改善程度较单用硫酸特布他林更明显,扩张支气管作用时间更长,副作用并不增加。
Objective To observe the effect of inhalation of beta 2 agonist terbutaline sulphate and lidocaine on asthma. Methods Sixty-nine patients with moderate-to-severe bronchial asthma were randomly divided into treatment group (n = 35) and control group (n = 34). Patients in moderate-severe asthma exacerbation group were treated with inhalation of terbutaline sulfate and lidocaine ) And compared with terbutaline sulphate alone (control group). The clinical manifestations were observed. The changes of PE-FR, FEV1 and FVC were monitored. Results All patients before treatment PEFR, FEV1, FVC were less than expected. After treatment, PEFR, FEV1, FVC in both groups were significantly increased and clinical symptoms were significantly controlled, the treatment group was more obvious, the difference between the two groups was statistically significant (P <0.01). CONCLUSIONS: Terbutaline sulfate and lidocaine inhalation are effective in treating moderate-severe asthma. The clinical symptoms and pulmonary function improvement are more obvious than terbutaline sulphate alone. Bronchial expansion is longer and the side effects are not increased.